New drug MSD-001 tested in healthy volunteers for safety
NCT ID NCT06702332
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-stage trial tested a single dose of MSD-001 in 47 healthy adults to see if it is safe and how the body processes it. The drug is being developed as part of a future combination treatment for mental health conditions. The study is now complete.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MSD-001
What this could lead to
If successful, this study could pave the way for developing a new treatment for mental health disorders.
What could go wrong
This is a very early Phase 1 trial in healthy people, not patients. It only tests safety and dosing, not whether the drug works for any condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MENTAL HEALTH DISORDERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre for Human Drug Research
Leiden, South Holland, Netherlands